{"organizations": [], "uuid": "d44497f81396667ce08c2068fb92acf4aa4eb23f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/5", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/04/26/globe-newswire-biocryst-to-announce-first-quarter-2018-financial-results-on-may-8.html", "country": "US", "domain_rank": 767, "title": "BioCryst to Announce First Quarter 2018 Financial Results on May 8", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.162, "site_type": "news", "published": "2018-04-26T14:00:00.000+03:00", "replies_count": 0, "uuid": "d44497f81396667ce08c2068fb92acf4aa4eb23f"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/04/26/globe-newswire-biocryst-to-announce-first-quarter-2018-financial-results-on-may-8.html", "ord_in_thread": 0, "title": "BioCryst to Announce First Quarter 2018 Financial Results on May 8", "locations": [], "entities": {"persons": [{"name": "jon p. stonehouse", "sentiment": "none"}, {"name": "bill sheridan", "sentiment": "none"}, {"name": "thomas r. staab", "sentiment": "none"}], "locations": [{"name": "n.c.", "sentiment": "none"}], "organizations": [{"name": "nas", "sentiment": "negative"}, {"name": "biocryst", "sentiment": "negative"}, {"name": "biocryst pharmaceuticals, inc.", "sentiment": "neutral"}, {"name": "biocryst pharmaceuticals biocryst pharmaceuticals", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "RESEARCH TRIANGLE PARK, N.C., April 26, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that its first quarter 2018 financial results will be reported on Tuesday, May 8, 2018.\nBioCryst will host a conference call and webcast at 11:00 a.m. Eastern Time to discuss financial results and to provide an update regarding the Company's clinical development programs. The call will be led by Jon P. Stonehouse, President & Chief Executive Officer, Thomas R. Staab II, Senior Vice President & Chief Financial Officer, and Dr. Bill Sheridan, Senior Vice President and Chief Medical Officer.\nLinks to a live audio webcast and replay of the presentation may be accessed on the BioCryst website events page at https://biocryst.gcs-web.com/events .\nAbout BioCryst Pharmaceuticals\nBioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule medicines that address both common and rare conditions. BioCryst has several ongoing development programs including BCX7353, an oral treatment for hereditary angioedema, galidesivir, a potential treatment for filoviruses, and a preclinical program to develop oral Alk-2 inhibitors for the treatment of fibrodysplasia ossificans progressive (FOP). RAPIVAB Â® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst's first approved product and has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan, Korea and the European Union. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the Company's website at www.BioCryst.com .\nThis press release contains , including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the . Please refer to the documents BioCryst files periodically with the SEC and located at https://biocryst.gcs-web.com/financial-information/sec-filings .\nBCRXW\nCONTACT: Thomas Staab, BioCryst Pharmaceuticals, +1-919-859-7910\nSource:BioCryst Pharmaceuticals, Inc.", "external_links": ["https://biocryst.gcs-web.com/financial-information/sec-filings", "https://www.globenewswire.com/Tracker?data=464taVVLV_QDnrrgwhslJV08KkN_VLYIQUBIbMrg32DiMlstTJpZ9qHZxdwxiNA2-irSFVVf1fC1IgJXcWKIVVnRQbhRDOWTfGd7rR8bpcgnQ0B95Cn1uTJKQEL74xRp", "https://www.globenewswire.com/Tracker?data=464taVVLV_QDnrrgwhslJV08KkN_VLYIQUBIbMrg32Dz-2qQC8BUv_Lc_5NmL95pPlO8whJMekyC2K9vGzogiNOHBD9GUv7FA0UJbMDO9ilxkVN4Oo06lzJ0EAsi4cXK6ss1vS0sHMmxqsuWpzhY-jpjegc1APhgUUhshWdEWlliioFtocKXGrI68SAUB9xFJ53hovBFHvcpuQdsIyjP5w==", "https://biocryst.gcs-web.com/events", "https://www.globenewswire.com/NewsRoom/AttachmentNg/4cf348c1-58fd-4ced-b5a6-d241bd5414e9", "https://www.globenewswire.com/Tracker?data=5gyRTcoWmUNVr0Z4ws7SiK9ism65sVcPuEi4x5csDhBXiL702XU-pjchhGLhGERM_0SdXOepj-fEBc8rsuDmvg==", "https://www.globenewswire.com/Tracker?data=ynrBEmchqqrFuhNGdnUnqrWooYrKcdk-kDvITHYPG9aDMDv4JBFpvKOrcl21QjyVCgi-AlfS6q5bC7n1-MoVMnmTXE0s7VP2PiItgK05y4s="], "published": "2018-04-26T14:00:00.000+03:00", "crawled": "2018-04-26T15:01:15.006+03:00", "highlightTitle": ""}